9 results about "PSMA Antibody" patented technology

The invention relates to an anti-PSMA antibody-drug conjugate and a medical application thereof. Specifically, the anti-PSMA antibody-drug conjugate is shown as a general formula Pc-L-Y-D, Pc is an anti-PSMA antibody or an antigen binding fragment thereof, and L, Y and n are defined as in the specification.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

The present invention relates to anti-adhesin 2 antibodies or antigen-binding fragments thereof, anti-PSMA antibodies or antigen-binding fragments thereof, bispecific antibody constructs that bind to adhesin 2 and PSMA, and antibody-drug conjugates comprising such antibodies. The invention also relates to the use of said antibody-drug conjugate for the treatment of cancer.

The present disclosure relates to antibody conjugates comprising an antibody that specifically binds to a PSMA protein conjugated to exatecan, and related therapeutic uses.

Provided herein are novel anti-CD28 x anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28 x anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-PSMA antibodies) for the treatment of prostate cancers.

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates) thereof that bind PSMA, as well as STING agonist linker-drug conjugates and preparation thereof, are disclosed. The disclosure further relates to methods and compositions for use in the treatment of, e.g., cancer by administering the compositions provided herein.

The present disclosure provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. In some embodiments, the antibodies of the disclosure bind human PSMA with high affinity and bind CD3 to induce proliferation of human T cells. The disclosure includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of tumor cells expressing PSMA. In some embodiments, the present disclosure provides bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD3 and a second antigen binding molecule that specifically binds human PSMA. In some embodiments, the bispecific antigen binding molecules of the present disclosure are capable of inhibiting the growth of prostate tumors expressing PSMA.The antibodies and bispecific antigen binding molecules of the disclosure are useful for the treatment of diseases and disorders where a targeted, upregulated or induced immune response is desirable and / or therapeutically advantageous. For example, the antibodies of the disclosure are useful for the treatment of various cancers.

The application discloses an engineered anti-PSMA-TAT@celinexor exosome for treating castration-resistant prostate cancer and a preparation method and application thereof. The exosome is constructed by gene engineering and chemical modification technology, and an anti-PSMA antibody fragment with prostate-specific membrane antigen targeting function and a cell-penetrating peptide TAT are co-displayed on the surface of the exosome, and an anticancer drug celinexor is efficiently loaded, so that a novel targeted drug delivery system is constructed. The system realizes the enrichment of the exosome in the prostate cancer tissue site by using anti-PSMA, and further realizes the double precise targeting from the tissue to the cell and then to the nucleus by the aid of the TAT peptide to promote the drug to penetrate the cell membrane and further target the nucleus. The strategy not only significantly enhances the accumulation and efficacy of celinexor in the nucleus of the prostate cancer, but also effectively reduces the toxic side effects of celinexor on normal tissues through the natural biocompatibility and targeted delivery characteristics of the exosome, thereby improving the treatment safety.

The present invention relates to prostate-specific membrane antigen antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates (ADCs). The present invention provides a method for treating a subject with an anti-PSMA ADC to inhibit, prevent, or treat a PSMA-related disease or cancer, including prostate cancer. The present disclosure also provides pharmaceutical compositions containing an anti-PSMA ADC suitable for administration to a human subject.